Early versus delayed administration of granulocyte-colony stimulating factor following chemotherapy in pediatric patients with Ewing sarcoma

Abstract

Background

The optimal timing of initiating granulocyte-colony stimulating factor following chemotherapy in pediatric patients has not been clearly defined. This study aimed to compare the administration of granulocyte-colony stimulating factor on day 1 versus day 3 postchemotherapy in pediatric patients with Ewing sarcoma.

Method

A retrospective study of pediatric patients with Ewing sarcoma who received granulocyte-colony stimulating factor following chemotherapy between January 2016 and September 2018 at a comprehensive cancer center. The institution’s chemotherapy protocol for Ewing sarcoma was modified in April 2017 to include granulocyte-colony stimulating factor initiation on day 3 instead of day 1 post-chemotherapy. Febrile neutropenia requiring hospitalization, duration of hospital stay, and chemotherapy delay were compared for patients before and after the protocol change.

Results

Over the study period, 250 cycles were evaluated with day 1 granulocyte-colony stimulating factor and 221 cycles with day 3 granulocyte-colony stimulating factor. There were no differences between the day 1 and day 3 groups in the number of cycles associated with Febrile neutropenia requiring hospitalization (34 vs. 19, p = 0.086), and the length of Febrile neutropenia-related hospitalization (mean 4 ± 2.1 vs. 4.6 ± 1.8, p = 0.123). However, delay in chemotherapy due to neutropenia was reported in significantly more cycles in the day 1 group, compared to the day 3 group (37 vs. 16, p = 0.01).

Conclusions

Febrile neutropenia resulting in hospital admission and the length of hospital stay was not different between pediatric patients with Ewing sarcoma who received granulocyte-colony stimulating factor on day 1 or day 3 post-chemotherapy. Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1. Larger studies are required to fully determine the impact of delayed initiation of granulocyte-colony stimulating factor.

Keywords

Delayed administration early administration granulocyte colony-stimulating factor pediatrics Sarcoma ewing

Get full access to this article

View all access options for this article.

References

Bennett

Djulbegovic

Norris

, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013; 368(12): 1131–1139.

Crawford

Kreisman

Garewal

, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 1997; 8: 1117–1124.

Rahiala

Perkkiö

Riikonen

. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol 1999; 32: 326–330.

Crawford

Becker

Armitage

, et al. Myeloid growth factors. J Natl Compr Canc Netw 2017; 15: 1520–1541.

Milano-Bausset

Gaudart

Rome

, et al. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clin Therapeut 2009; 31(Pt 2): 2388–2395.

Womer

West

Krailo

, et al. Randomized controlled trial of interval- chemotherapy for the treatment of localized Ewing sarcoma: a report from the children’s oncology group. J Clin Oncol 2012; 30(33): 4148–4154.

American Society of Clinical Oncology (ASCO), www.cancer.net/navigating-cancer-care/side-effects/neutropenia (accessed February 2018).

Pai

Fernandez

Laudick

, et al. Delayed administration of filgrastim (G-CSF) following APBSCT in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF. Pediatr Blood Cancer 2010; 54: 728–733.

Faucher

Le Corroller

Chabannon

. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: a randomized study. Bone Marrow Transpl 1996; 17: 533–536.

10.

Cetkovský

Koza

Jindra

, et al. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transpl 1997; 20: 639–641.

11.

Bolwell

Pohlman

Andresen

, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transpl 1998; 21: 369–373.

12.

Colby

McAfee

Finkelstein

, et al. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transpl 1998; 21: 1005–1010.

13.

Linot

Augereau

. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 2014; 22(10): 2831–2837.